Stockscreener 앱 받기
4.28
4.68%
-0.21
Adicet Bio Inc 주식(ACET)의 최신 뉴스
A new hire waits a year to gain the right to buy Adicet shares - Stock Titan
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Every patient in Adicet's lupus study stopped immune-suppressing drugs - Stock Titan
Adicet Bio (Nasdaq:ACET)Stock Analysis - Simply Wall Street
Adicet Bio (NasdaqCM:ACET) Stock Forecast & Analyst Predictions - Simply Wall Street
At $10.99 a share, Gossamer Bio (GOSS) director Sandra Milligan receives a stock option. - Stock Titan
Gossamer Bio grants director options on 10,000 shares - Stock Titan
Devpratim Chakraborty, Brigit SVP, reported no direct Upbound Group (UPBD) shares as of September 22. - Stock Titan
[Form 3] Electra Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Red Robin Gourmet Burgers, Inc.Common Stock (NQ: RRGB - The Chronicle-Journal
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adicet Bio (NASDAQ:ACET) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - marketbeat.com
Stock option sale planned at ScanSource (NASDAQ: SCSC) for 2026 - Stock Titan
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - marketbeat.com
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - stocktitan.net
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Stock Rating Lowered by Wall Street Zen - marketbeat.com
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com India
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com UK
Adicet Bio receives FDA clearance for prostate cancer trial - investing.com
FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy - Stock Titan
Here's Why You Should Add ACET Stock to Your Portfolio Now - Yahoo Finance
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Yahoo Finance
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Yahoo Finance
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
0.68%
3.98%
자본화:
|
볼륨(24시간):